AnaptysBio-Tesaro trial heads to post-trial briefs, argument set for Oct. 20
Reuters2026/07/30 20:32- AnaptysBio disclosed post-trial briefing dates in its Delaware Chancery Court dispute with Tesaro and parent GlaxoSmithKline over a collaboration license.
- The company seeks a declaration that Tesaro materially breached the agreement, alleging GlaxoSmithKline tortiously interfered.
- The consolidated trial ran July 14-17, 2026; opening brief due Aug. 21, defense brief due Sept. 25, reply due Oct. 9.
- Post-trial argument is scheduled for Oct. 20, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Circle obtains Major Payment Institution license in Singapore
Crypto prices
More
